Filing Details

Accession Number:
0001553878-17-000013
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-17 18:45:21
Reporting Period:
2017-05-16
Filing Date:
2017-05-17
Accepted Time:
2017-05-17 18:45:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1514291 Michael Mason C/O Alnylam Pharmaceuticals, Inc.
300 Third Street
Cambridge MA 02142
Vp, Finance And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-16 5,625 $18.66 5,625 No 4 M Direct
Common Stock Acquisiton 2017-05-16 3,750 $7.10 9,375 No 4 M Direct
Common Stock Disposition 2017-05-16 9,375 $70.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-05-16 3,750 $0.00 3,750 $7.10
Common Stock Stock Option (Right to Buy) Disposition 2017-05-16 5,625 $0.00 5,625 $18.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-11-30 No 4 M Direct
0 2022-12-20 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,176 Indirect By Managed Account
Footnotes
  1. All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016.
  2. The reporting person owns 2,176 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
  3. The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.